Melanie A. Morrison

Melanie A. Morrison

Auto-generated profile, based on publicly available information

Melanie A. Morrison

Department of Radiology and Biomedical Imaging, University of California, San Francisco, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2026 in Nature
Verified
Journal Article
Open access
PDF file
JRJianxun Ren
Jianxun Ren
WZWei Zhang
Wei Zhang
LDLouisa Dahmani
Louisa Dahmani
EGEvan M. Gordon
Evan M. Gordon
SLShenshen Li
Shenshen Li
HLHesheng Liu
Hesheng Liu
Parkinson’s disease (PD) is an incurable neurological disorder that often begins insidiously with sleep disturbances and somatic symptoms, progressing to whole-body motor and cognitive symptoms1,2,3,4,5. Dysfunction of the somato-cognitive action network (SCAN)—which is thought to control action execution6,7 by coordinating arousal, organ physiology and whole-body motor plans with behavioural motivation—is a potential contributor to the diverse clinical manifestations of PD. To investigate the role of the SCAN in PD pathophysiology and treatments (medications, deep-brain stimulation (DBS), transcranial magnetic stimulation (TMS) and MRI-guided focused ultrasound stimulation (MRgFUS)), we built a large (n = 863), multimodal, multi-intervention clinical imaging dataset. Resting-state functional connectivity revealed that the substantia nigra and all PD DBS targets (subthalamic nucleus, globus pallidus and ventral intermediate thalamus) are selectively connected to the SCAN rather than to effector-specific motor regions. Importantly, PD was characterized by specific hyperconnectivity between the SCAN and the subcortex. We therefore followed six PD cohorts undergoing DBS, TMS, MRgFUS and levodopa therapy using precision resting-state functional connectivity and electrocorticography recording. Efficacious treatments reduced SCAN-to-subcortex hyperconnectivity. Targeting the SCAN instead of effector regions doubled the efficacy of TMS treatments. Focused ultrasound treatment benefits increased when the target was closer to the thalamic SCAN sweet spot. Thus, SCAN hyperconnectivity is central to PD pathophysiology and its alleviation is a hallmark of successful neuromodulation. Targeting functionally defined subcortical SCAN nodes may improve existing therapies (DBS, MRgFUS), whereas cortical SCAN targets offer effective non-invasive or minimally invasive neuromodulation for PD.

8 November 2023 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
SSStephanie S. Sandoval-Pistorius
Stephanie S. Sandoval-Pistorius
MHMallory Hacker
Mallory Hacker
AWAllison C. Waters
Allison C. Waters
JWJing Wang
Jing Wang
NPNicole R. Provenza
Nicole R. Provenza
SCStephanie Cernera
Stephanie Cernera
Deep brain stimulation (DBS) is an effective therapy for various neurologic and neuropsychiatric disorders, involving chronic implantation of electrodes into target brain regions for electrical stimulation delivery. Despite its safety and efficacy, DBS remains an underutilized therapy. Advances in the field of DBS, including in technology, mechanistic understanding, and applications have the potential to expand access and use of DBS, while also improving clinical outcomes. Developments in DBS technology, such as MRI compatibility and bidirectional DBS systems capable of sensing neural activity while providing therapeutic stimulation, have enabled advances in our understanding of DBS mechanisms and its application. In this review, we summarize recent work exploring DBS modulation of target networks. We also cover current work focusing on improved programming and the development of novel stimulation paradigms that go beyond current standards of DBS, many of which are enabled by sensing-enabled DBS systems and have the potential to expand access to DBS.

20 January 2019 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Closed access
PDF file
MMMelanie A. Morrison
Melanie A. Morrison
CHChristopher P. Hess
Christopher P. Hess
JCJennifer L. Clarke
Jennifer L. Clarke
NBNicholas Butowski
Nicholas Butowski
SCSusan M. Chang
Susan M. Chang
JLJanine M. Lupo
Janine M. Lupo

17 December 2020 in Blood
Verified
Journal Article
Open access
PDF file
NCNichola Cooper
Nichola Cooper
MMMelanie A. Morrison
Melanie A. Morrison
CVCamelia Vladescu
Camelia Vladescu
AHAlice C. J. Hart
Alice C. J. Hart
DPDeena Paul
Deena Paul
AWAdam D Waldman
Adam D Waldman
Management of symptoms and prevention of life-threatening hemorrhage in immune thrombocytopenia (ITP) must be balanced against adverse effects of therapies. Because current treatment guidelines based on platelet count are confounded by variable bleeding phenotypes, there is a need to identify new objective markers of disease severity for treatment stratification. In this cross-sectional prospective study of 49 patients with ITP and nadir platelet counts <30 × 109/L and 18 aged-matched healthy controls, we used susceptibility-weighted magnetic resonance imaging to detect cerebral microbleeds (CMBs) as a marker of occult hemorrhage. CMBs were detected using a semiautomated method and correlated with clinical metadata using multivariate regression analysis. No CMBs were detected in health controls. In contrast, lobar CMBs were identified in 43% (21 of 49) of patients with ITP; prevalence increased with decreasing nadir platelet count (0/4, ≥15 × 109/L; 2/9, 10-14 × 109/L; 4/11, 5-9 × 109/L; 15/25 <5 × 109/L) and was associated with longer disease duration (P = 7 × 10−6), lower nadir platelet count (P = .005), lower platelet count at time of neuroimaging (P = .029), and higher organ bleeding scores (P = .028). Mucosal and skin bleeding scores, number of previous treatments, age, and sex were not associated with CMBs. Occult cerebral microhemorrhage is common in patients with moderate to severe ITP. Strong associations with ITP duration may reflect CMB accrual over time or more refractory disease. Further longitudinal studies in children and adults will allow greater understanding of the natural history and clinical and prognostic significance of CMBs.

20 September 2020 in Radiotherapy and Oncology
Verified
Journal Article
Open access
MMMelanie A. Morrison
Melanie A. Morrison
SMSabine Mueller
Sabine Mueller
EFErin Felton
Erin Felton
AJAngela Jakary
Angela Jakary
SSSchuyler Stoller
Schuyler Stoller
JLJanine M. Lupo
Janine M. Lupo
Radiation therapy (RT) is essential to the management of many brain tumors, but has been known to lead to cognitive decline and vascular injury in the form of cerebral microbleeds (CMBs). In a subset of children, adolescents, and young adults recruited from a larger trial investigating arteriopathy and stroke risk after RT, we evaluated the prevalence of CMBs after RT, examined risk factors for CMBs and cognitive impairment, and related their longitudinal development to cognitive performance changes. Twenty-five patients (mean 17 years, range:10–25 years) underwent 7-Tesla MRI and cognitive assessment. 19 patients were treated with whole-brain or focal RT 1-month to 20-years prior, while 6 non-irradiated patients with posterior-fossa tumors served as controls. CMBs were detected on 7T susceptibility-weighted imaging (SWI) using semi-automated software, a first use in this population. CMB detection sensitivity with 7T SWI was higher than previously reported at lower field strengths, with one or more CMBs detected in 100% of patients treated with RT at least 1-year prior. CMBs were localized to dose-targeted brain volumes with risk factors including whole-brain RT (p=0.05), a higher RT dose (p=0.01), increasing time since RT (p=0.03), and younger age during RT (p=0.01). Apart from RT dose, these factors were associated with impaired memory performance. Follow-up data in a subset of patients revealed a proportional increase in CMB count with worsening verbal memory performance (r=−0.85,p=0.03). Treatment with RT during youth is associated with the chronic development of CMBs that evolve with memory impairment over time.

1 July 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
DSDevin Schoen
Devin Schoen
SDSkyler Deutsch
Skyler Deutsch
JMJuhi Mehta
Juhi Mehta
SWSarah Wang
Sarah Wang
JKJohn Kornak
John Kornak
MMMelanie A. Morrison
Melanie A. Morrison
While deep brain stimulation (DBS) remains an effective therapy for Parkinson’s disease (PD), sources of variance in patient outcomes are still not fully understood, underscoring a need for better prognostic criteria. Here, we leveraged routinely collected T1-weighted (T1-w) magnetic resonance imaging (MRI) data to derive patient-specific measures of brain structure and evaluate their usefulness in predicting changes in PD medications in response to DBS. Preoperative T1-w MRI data from 231 patients with PD were used to extract regional measures of fractal dimension (FD), sensitive to the structural complexities of cortical and subcortical brain. FD was validated as a biomarker of PD progression through comparison of patients with PD and healthy controls (HCs). This analysis revealed significant group differences in FD across nine brain regions, including frontal, occipital, insular, and basal ganglia areas, which supports its utility as a marker of PD. We evaluated the impact of adding imaging features (FD) to a clinical model that included demographics and clinical parameters (age, sex, total number and location of DBS electrodes), and preoperative motor response to levodopa. This model aimed to explain variance and predict changes in medication following DBS. Regression analysis revealed that inclusion of the FD of distributed brain areas correlated with post-DBS reductions in medication burden, explaining an additional 13.6% of outcome variance (R2 = 0.388) compared to clinical features alone (R2 = 0.252). Hypergraph-based classification learning tasks achieved an area under the receiver operating characteristic curve of 0.64 when predicting with clinical features alone, versus 0.76 when combining clinical and imaging features. These findings demonstrate that PD effects on brain morphology linked to disease progression influence DBS outcomes. The work also highlights FD as a potentially useful imaging biomarker to enhance DBS candidate selection criteria for optimized treatment planning.